

47th Union World Conference on Lung Health, Liverpool, UK

Workshop: “Confronting Resistance: Ensuring access to new TB drugs in the WHO European Region with focus on Eastern Europe and Central Asia”.

Organizers: World Health Organization Regional Office for Europe and Partners In Health/Russia

Date: October 26, 2016, from 8:00 – 14:30

Place: Session room 12

Chairs: Drs. Irina Vasilyeva, Masoud Dara, Jennifer Furin

Coordinators: Drs. Martin van den Boom, Askar Yedilbayev

Language: English and Russian, simultaneous translation provided.

Background:

WHO recommends bedaquiline and delamanid for the therapy of DR-TB. The WHO European Region has the highest rates of DR-TB worldwide. Introduction of new TB drugs has lagged somewhat behind the need for new treatments. Even after their approval by stringent regulatory authorities in some countries, the actual number of patients treated with bedaquiline and delamanid is still lower than the actual need. Several settings have already reported some successes in using bedaquiline and delamanid under compassionate use or programmatic conditions but these results have not yet been presented broadly. Lack of knowledge and availability of materials on clinical and programmatic use of new drugs for TB is one of major barriers to accelerate access to new treatments. Limited availability of materials and tools in local languages on regimen design, safety and effectiveness is another challenge, which affects their uptake by national TB programs.

Objectives:

1. To present experiences with introduction of new drugs at country level;
2. To share good practices for adequate and rational use of new TB drugs, including training materials;
3. To help develop a network of medical and public health providers who can form a community of practice, providing support to one another in the expansion of new drug introduction.

Agenda:

	Time	Title	Speaker
1	8:00 – 8:10	Opening remarks	Chairs
2	8:10 – 8:40	WHO perspective of sharing knowledge on new TB drugs: regional experience.	Dr. Masoud Dara, Belgium
3	8:40 – 9:10	Global tendency toward increasing access to Bedaquiline and Delamanid.	Dr. Jennifer Furin, United States
4	9:10 – 9:40	Ensuring adequate supply of new TB drugs.	Dr. Nigorsulton Muzafarova, Switzerland
	9:40 – 10:00	Break	
5	10:00 – 10:30	Update from the work of new and repurposed TB drug introduction from the WHO Regional Office for Europe.	Dr. Martin van den Boom, Denmark
6	10:30 – 11:00	Field management of patients with new TB drugs: examples from the endTB Project.	Dr. Michael Rich, United States
7	11:00 – 11:30	Early implementing country: Use of Bedaquiline, national roll-out, needs and challenges, example from the Russian Federation.	Dr. Irina Vasilyeva, Russian Federation
8	11:30 – 12:00	Early implementing country: Monitoring and management of patients in the setting of new TB drugs, practical tools: example from Latvia.	Dr. Liga Kuksa, Latvia
	12:00 – 12:30	Country report: working with the national drug regulatory authorities or around regulations to import the new TB drugs into countries, example from Kazakhstan.	Dr. Elmira Berikova, Kazakhstan
9	12:30 – 13:00	Country report: experience of the use of new TB drugs, example from Georgia.	Dr. Nino Lomtadze, Georgia
11	13:00 – 13:30	Country report: experience with pharmacovigilance/aDSM, example from Belarus.	Dr. Alena Skrahina, Belarus
12	13:30 – 14:00	Final discussion and Closing	Chairs